[go: up one dir, main page]

YU34896A - Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije - Google Patents

Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije

Info

Publication number
YU34896A
YU34896A YU34896A YU34896A YU34896A YU 34896 A YU34896 A YU 34896A YU 34896 A YU34896 A YU 34896A YU 34896 A YU34896 A YU 34896A YU 34896 A YU34896 A YU 34896A
Authority
YU
Yugoslavia
Prior art keywords
intermediates
pharmaceutical compositions
indole
glycinamides
carbonyl
Prior art date
Application number
YU34896A
Other languages
English (en)
Inventor
Bernard Hulin
Judith Lee Treadway
William Holt Martin
Dennis Jay Hoover
Douglas Phillips
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU34896A publication Critical patent/YU34896A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Ovaj pronalazak se odnosi na odredjene indol-2-karboksamide korisne kao antidijabetski agensi, formule I u kojoj su R1, R2, R3 i R4 vodonik, A je -C(H)= kada je tačkasta linija veza, R5 je vodonik, metil ili etil, R6 je karboksi, (C1-C6) alkoksikarbonil ili benziloksikarbonil, i R10 i R11 su vodonik, halogen ili cijano. Takodje su opisani njihovi intermedijari i farmaceutske kompozicije koje sadrže jedinjenja formule I:
YU34896A 1995-06-06 1996-06-05 Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije YU34896A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000442 WO1996039384A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Publications (1)

Publication Number Publication Date
YU34896A true YU34896A (sh) 1999-09-27

Family

ID=11004338

Family Applications (1)

Application Number Title Priority Date Filing Date
YU34896A YU34896A (sh) 1995-06-06 1996-06-05 Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije

Country Status (37)

Country Link
US (1) US6107329A (sh)
EP (1) EP0832065B1 (sh)
JP (1) JP3314938B2 (sh)
KR (1) KR100191992B1 (sh)
CN (2) CN1142492A (sh)
AP (1) AP623A (sh)
AR (1) AR003955A1 (sh)
AT (1) ATE206702T1 (sh)
AU (1) AU701465B2 (sh)
BG (1) BG100547A (sh)
BR (1) BR9602542A (sh)
CA (2) CA2342471C (sh)
CO (1) CO4700440A1 (sh)
CZ (1) CZ157396A3 (sh)
DE (1) DE69523182T2 (sh)
DK (1) DK0832065T3 (sh)
FI (1) FI974436A (sh)
HR (1) HRP960244A2 (sh)
HU (1) HUP9601475A2 (sh)
IL (1) IL118029A0 (sh)
IS (1) IS4341A (sh)
LV (1) LV11613B (sh)
MA (1) MA23866A1 (sh)
MX (1) MX9709875A (sh)
NO (2) NO306398B1 (sh)
NZ (1) NZ286460A (sh)
OA (1) OA10581A (sh)
PL (1) PL314561A1 (sh)
RU (1) RU2143424C1 (sh)
SG (1) SG44947A1 (sh)
SI (1) SI9600177A (sh)
SK (1) SK69996A3 (sh)
TN (1) TNSN96072A1 (sh)
TR (1) TR199600456A2 (sh)
TW (1) TW346485B (sh)
WO (1) WO1996039384A1 (sh)
YU (1) YU34896A (sh)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832065B1 (en) * 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
IL131659A (en) 1997-04-15 2005-07-25 Csir Pharmaceutical compositions having appetite suppressant activity
UA57811C2 (uk) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
DE60045474D1 (de) 1999-01-13 2011-02-17 Univ New York State Res Found Neues verfahren zum erschaffen von proteinkinase-inhibitoren
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) * 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US20060160740A1 (en) * 1999-10-21 2006-07-20 Suad Efendic Use of GLP-1 or analogs in treatment of stroke
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
RU2002111660A (ru) 1999-11-04 2003-11-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Непептидные замещенные бензотиазепины в качестве антагонистов вазопрессина
EP1741447B1 (en) 2000-01-21 2013-09-18 Novartis AG Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
US6838465B2 (en) 2000-05-11 2005-01-04 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
ES2347137T3 (es) 2000-10-20 2010-10-26 Amylin Pharmaceuticals, Inc. Tratamiento de miocardio hibernante y cardiomiopatia diabetica con un peptido gpl-1.
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1392679B1 (de) 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2464214C (en) 2001-10-22 2011-02-08 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
CA2465382A1 (en) * 2001-10-29 2003-05-08 Japan Tobacco Inc. Indole compound and medicinal use thereof
FR2834214B1 (fr) * 2001-12-28 2004-09-24 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un acide 4-oxo-butanoique et son utilisation pour traiter le diabete
JP2005514460A (ja) * 2002-01-18 2005-05-19 ファイザー・プロダクツ・インク グリコーゲンホスホリラーゼ阻害剤を製造するための中間体
MXPA03000966A (es) 2002-02-28 2003-09-04 Pfizer Prod Inc Agentes antidiabeticos.
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
WO2003091213A1 (fr) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Derives d'amide ou sels de ces derives
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
BR0316099A (pt) 2002-11-07 2005-09-27 Pfizer Prod Inc Agentes antidiabéticos
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
CN1964630A (zh) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
US7595403B2 (en) 2003-04-01 2009-09-29 Eli Lilly And Company Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
BRPI0409465A (pt) * 2003-04-17 2006-05-02 Pfizer Prod Inc derivados de carboxamida como agentes antidiabéticos
WO2004096768A1 (en) * 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
WO2004103958A2 (en) * 2003-05-19 2004-12-02 Michigan State University Preparation of hymenialdisine derivatives and use thereof
US7405210B2 (en) * 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
UA84146C2 (ru) * 2003-05-21 2008-09-25 Прозидион Лимитед Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
JP4579239B2 (ja) * 2003-06-17 2010-11-10 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療または予防するためのジペプチジルペプチダーゼ阻害剤としてのシクロヘキシルグリシン誘導体
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
ES2524916T3 (es) 2003-11-12 2014-12-15 Sino-Med International Alliance, Inc. Compuestos heterocíclicos de ácido borónico
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
WO2006017292A1 (en) 2004-07-12 2006-02-16 Phenomix Corporation Constrained cyano compounds
US7884079B2 (en) * 2004-12-27 2011-02-08 Miller Landon C G 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) * 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
GB0425919D0 (en) * 2004-11-25 2004-12-29 Prosidion Ltd Indole-2-carboxylic acid amides
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
WO2006059164A2 (en) 2004-12-02 2006-06-08 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amides
US8691835B2 (en) 2004-12-27 2014-04-08 Landon C. G. Miller 4 aminopyridine and a pharmaceutical composition for treatment of neuronal disorders
KR20080012304A (ko) * 2005-05-23 2008-02-11 니뽄 다바코 산교 가부시키가이샤 피라졸 화합물 및 이들 피라졸 화합물을 포함하여이루어지는 당뇨병 치료약
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
HRP20140091T4 (hr) 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
CN100519524C (zh) * 2005-09-29 2009-07-29 中国人民解放军军事医学科学院毒物药物研究所 吲哚丙烯酸衍生物及其用于制备免疫抑制剂的用途
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
MX2009002047A (es) * 2006-09-13 2009-03-06 Sanofi Aventis Derivados de isoserina para uso como inhibidores del factor ixa de la coagulacion.
WO2008062739A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles et leur utilisation en tant que médicaments
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2008077079A1 (en) * 2006-12-18 2008-06-26 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ES2371393T3 (es) 2007-03-12 2011-12-30 Zadec Aps Extracto antidiabético de rooibos.
CN101279955B (zh) * 2007-04-03 2012-11-28 北京摩力克科技有限公司 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
CA2731097A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Organic compounds
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
CN102453001B (zh) * 2010-10-22 2016-06-01 中国医学科学院药物研究所 硫代吗啉类化合物及其制备方法和用途
US9409880B2 (en) * 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
CA2828343A1 (en) 2011-03-04 2012-09-13 The Scripps Research Institute Edn3-like peptides and uses thereof
JP5959075B2 (ja) * 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
MX344109B (es) 2011-10-25 2016-12-05 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
RU2618628C1 (ru) 2013-04-17 2017-05-05 Пфайзер Инк. Производные N-пиперидин-3-илбензамида для лечения сердечно-сосудистых заболеваний
CN103497181B (zh) 2013-09-30 2016-03-30 承德医学院 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途
WO2015131113A1 (en) * 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途
CN108191845A (zh) * 2018-02-12 2018-06-22 李化绪 一种异恶唑亚氨基类化合物及其在降血脂药物中的应用
CA3125765A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764610A (en) * 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4836846A (en) * 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) * 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) * 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4757151A (en) * 1985-11-14 1988-07-12 Warner-Lambert Company 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl]
US4902708A (en) * 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) * 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
HU204285B (en) * 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
US5034376A (en) * 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
MY103189A (en) * 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US5095004A (en) * 1987-03-25 1992-03-10 Bio-Mega Inc. Fluorine containing atrial natriuretic peptides
EP0288965A2 (de) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptide mit Phospholipase A2- hemmender Wirkung
US5128346A (en) * 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) * 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
US5346907A (en) * 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
EP0336356A3 (en) * 1988-04-05 1991-09-25 Abbott Laboratories Derivatives of tryptophan as cck antagonists
GB8810203D0 (en) * 1988-04-29 1988-06-02 Ici Plc Heterocyclic compounds
US4904846A (en) * 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
US5010089A (en) * 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (fr) * 1989-02-17 1993-11-05 Roussel Uclaf Nouveaux derives de l'acide 2-amino pentanedioique, leur procede de preparation et leur application comme medicaments
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) * 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) * 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
EP0431520B1 (en) * 1989-12-04 1995-02-08 G.D. Searle & Co. Heterocyclic acyl aminodiol beta-amino acid derivatives
HUT61575A (en) * 1990-02-09 1993-01-28 Rhone Poulenc Rorer Sa Process for producing n-acetamido-n-phenyl glycineamide derivatives and pharmaceutical compositions comprising same
WO1991013874A1 (fr) * 1990-03-07 1991-09-19 Rhone-Poulenc Rorer S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
JPH03294253A (ja) * 1990-04-12 1991-12-25 Shionogi & Co Ltd 消化管ホルモン拮抗物質
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) * 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) * 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof
EP0832065B1 (en) * 1995-06-06 2001-10-10 Pfizer Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
CZ157396A3 (en) 1997-03-12
EP0832065B1 (en) 2001-10-10
AU701465B2 (en) 1999-01-28
KR970001322A (ko) 1997-01-24
FI974436A (fi) 1998-01-27
TR199600456A2 (tr) 1996-12-21
HRP960244A2 (en) 1997-12-31
CA2224062A1 (en) 1996-12-12
IL118029A0 (en) 1996-08-04
LV11613B (en) 1997-04-20
JPH10511687A (ja) 1998-11-10
SG44947A1 (en) 1997-12-19
KR100191992B1 (ko) 1999-06-15
LV11613A (lv) 1996-12-20
TW346485B (en) 1998-12-01
PL314561A1 (en) 1996-12-09
CA2342471C (en) 2002-10-29
FI974436A0 (fi) 1997-12-05
CN1140709A (zh) 1997-01-22
IS4341A (is) 1996-12-07
SK69996A3 (en) 1997-08-06
OA10581A (en) 2002-08-28
EP0832065A1 (en) 1998-04-01
NO306398B1 (no) 1999-11-01
DE69523182T2 (de) 2002-02-07
AR003955A1 (es) 1998-09-30
TNSN96072A1 (fr) 2005-03-15
WO1996039384A1 (en) 1996-12-12
NO961664D0 (no) 1996-04-25
NO961664L (no) 1996-12-09
AP9600803A0 (en) 1996-04-30
NO990405L (no) 1999-01-28
DK0832065T3 (da) 2001-11-19
BR9602542A (pt) 1998-10-27
CA2224062C (en) 2001-09-04
AU5462696A (en) 1996-12-19
HUP9601475A2 (hu) 1998-09-28
CN1142492A (zh) 1997-02-12
RU2143424C1 (ru) 1999-12-27
CN1098838C (zh) 2003-01-15
US6107329A (en) 2000-08-22
JP3314938B2 (ja) 2002-08-19
SI9600177A (en) 1997-02-28
NO990405D0 (no) 1999-01-28
ATE206702T1 (de) 2001-10-15
MX9709875A (es) 1998-03-31
DE69523182D1 (en) 2001-11-15
AP623A (en) 1997-12-19
CO4700440A1 (es) 1998-12-29
NZ286460A (en) 1998-09-24
BG100547A (bg) 1996-12-31
MA23866A1 (fr) 1996-12-31
HU9601475D0 (en) 1996-07-29
CA2342471A1 (en) 1996-12-12

Similar Documents

Publication Publication Date Title
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
YU34796A (sh) Supstituisani n(indol-2-karbonil) гћві -alaninamid, njihovi derivati i farmaceutske smeše koje ih sadrže
MY125749A (en) Aralkyl and aralkylidene heterocyclic lactams and imides
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
DE69315079D1 (de) Beta-aminoalkyl und beta-n-peptidylaminoalkylborsäure
TR199800444A2 (xx) Hipolipidemik 1,4-benzotiazepin-1,1-diyoksitler.
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
BG105969A (en) Amine derivatives as protein inhibitors
MEP24608A (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
IL147651A0 (en) Isoxazoline derivative and herbicide containing the same as the active ingredient
ATE191485T1 (de) Mercaptoacetylamid-1,3,4,5- tetrahydrobenzo(c)azepin-3-ein disulfidderivate als enkephalinase und ace inhibitoren
SE9002206D0 (sv) New compounds
NO924929L (no) Farmasoeytisk aktive benzoquinazolinforbindelser
YU41198A (sh) Derivati pirolopirolona kao inhibitori neutrofilne elastaze
TR199902897T2 (xx) S�v� benz-izo-kuinolin t�revleri.
PE34996A1 (es) Nuevo derivado de pirrocarbazol
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
YU44301A (sh) 5ht1 antagonisti za antidepresantnu terapiju
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
DK0988312T3 (da) 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose
GR3023757T3 (en) Cyclic benzylamino, benzylamido and benzylimido derivatives as antipsychotic agents.
AP1396A (en) 1-Trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives.